ZIM Laboratories Limited
NSE: ZIMLAB · Pharmaceuticals · sector
₹126.69NSE close 2026-10-26
Key numbers
Market cap₹678 cr
Price₹126.69
52w high / low₹160 / ₹59
P/E154.5xSector median 27.9x
P/B2.3xSector median 2.9x
Book value₹55.3
Dividend yield–Sector median 0.48%
ROE1.4%Sector median 11.7%
ROCE4.4%Sector median 12.3%
OPM7.1%Sector median 14.0%
Debt / equity0.42xSector median 0.16x
EV/EBITDA26.9xSector median 18.6x
Interest cover1.4x
Current ratio1.45x
Sales growth 3y-2.1%Sector median +9.6%
Profit growth 3y-38.0%Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹43 cr vs borrowings ₹123 cr (FY26): borrowings are higher by ₹80 cr.
- Borrowings rose in each of the last 3 years (₹60 cr → ₹123 cr).
- Operating profit covered interest 1.4x in the last 12 months.
- Promoter holding fell by 2.96 percentage points in a year, to 30.30% (2026-09-30).
- Operating cash flow was below net profit in 1 of the last 4 years (FY24).
- Net loss in 3 of the last 8 quarters.
- Revenue was higher than a year earlier in 2 of the last 4 quarters.
- Other income was 295% of net profit in the last 12 months.
- No dividend in the last 4 financial years.
- Price ₹126.69 on 2026-10-26: -20.7% from the 52-week high, +113.6% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹150.47 · low ₹60.76
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 92 | 96 | 109 | 72 | 89 | 109 | 105 | 94 |
| EBITDA | 10 | 12 | 15 | 4 | 6 | 13 | 7 | 2 |
| OPM % | 10.3% | 12.0% | 13.4% | 5.9% | 6.5% | 11.8% | 6.8% | 2.6% |
| Other income | 1 | 2 | 2 | 1 | 2 | 2 | 6 | 1 |
| Net profit | 2 | 4 | 5 | -2 | -0 | 4 | 4 | -4 |
| EPS (₹) | 0.49 | 0.82 | 1.01 | -0.38 | -0.09 | 0.90 | 0.76 | -0.75 |
| Revenue YoY | -3.7% | +12.8% | -3.2% | +31.2% | ||||
| Profit YoY | -117.6% | +10.0% | -23.4% | – |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 399 | 367 | 379 | 374 | 397 |
| EBITDA | 52 | 41 | 44 | 30 | 28 |
| Net profit | 24 | 17 | 12 | 6 | 4 |
| EPS (₹) | 5.01 | 3.54 | 2.50 | 1.19 | 0.82 |
| Revenue growth | -7.8% | +3.2% | -1.2% | +7.5% | |
| Profit growth | -29.4% | -29.4% | -52.0% | -60.6% | |
| Dividend / share (₹) | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -2.1% | – | +7.6% |
| Net profit | -37.9% | – | -60.6% |
| EPS | -38.1% | – | – |
| Share price | – | +9.8% (2y) | +91.7% |
Balance sheet
| ₹ cr | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Shareholders' equity | 200 | 239 | 252 | 296 |
| Borrowings | 60 | 106 | 112 | 123 |
| Cash & equivalents | 8 | 10 | 2 | 43 |
| Total assets | 342 | 447 | 472 | 539 |
| Fixed assets | 104 | 157 | 158 | 156 |
| Capital work in progress | 18 | 24 | 44 | 59 |
| Investments | 0 | 0 | 0 | 0 |
| Receivables | 95 | 100 | 107 | 109 |
| Inventory | 54 | 81 | 86 | 94 |
| Payables | 58 | 62 | 70 | 73 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Cash from operations | 38 | 16 | 41 | 50 |
| Cash from investing | -36 | -73 | -40 | -56 |
| Cash from financing | 1 | 60 | -9 | 28 |
| Capex | 37 | 74 | 41 | 44 |
| Free cash flow | 1 | -58 | 0 | 5 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ROE % | 12.2% | 7.2% | 4.8% | 2.0% |
| ROCE % | 15.7% | 8.9% | 8.1% | 5.1% |
| Debtor days | 87 | 100 | 103 | 106 |
| Inventory days | 99 | 173 | 188 | 207 |
| Payable days | 107 | 133 | 151 | 161 |
| Cash conversion cycle (days) | 79 | 140 | 140 | 152 |
| Working capital days | 73 | 68 | 63 | 83 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 30.30% |
| FIIs | 0.17% |
| DIIs | 1.19% |
| of which Mutual funds | 1.18% |
| Public (non-institutions) | 68.34% |
| Quarter | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 33.26% | 33.26% | 33.26% | 33.26% | 30.30% | 30.35% | 30.36% | 30.30% |
| Promoter group | % |
|---|---|
| Anwar Siraj Daud | 25.03% |
| Sabbah Zulfiquar Kamal | 2.80% |
| Zulfiquar Kamal | 2.08% |
| Hasan Kamal | 0.19% |
| Shabbar Siraj Daud | 0.08% |
| Farhat Shabbar Daud | 0.07% |
| Tasneem Anwar Daud | 0.06% |
| Shirin Siraj Daud | 0.00% |
| Shakil Daud | 0.00% |
| Salman Anwar Daud | 0.00% |
| Lubna Daud | 0.00% |
| Nazneen Hussain | 0.00% |
| Nasir Murtaza Kamal | 0.00% |
| Mustafa Kamal | 0.00% |
| Seher Kamal | 0.00% |
| Public holders above 1% | % |
|---|---|
| Elimath Advisors Private Limited | 10.41% |
| Zakir S Vali | 9.41% |
| Florintree Trinex Llp | 8.88% |
| Investor Education And Protection Fund Authority Ministry Of Corporate Affairs | 3.57% |
| Bonanza Business Services Pvt Ltd | 2.31% |
| Dr Iguer Abdelmounaim | 2.17% |
| Quince Infotech And Leasing Private Limited | 1.27% |
| Laadki Trading And Investments Limited | 1.23% |
| Jyoti Bharat Sheth | 1.23% |
| Tata India Pharma & Healthcare Fund | 1.18% |
13,057 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| ZIMLAB | ₹678 cr | 154.5x | 2.3x | 1.4% | 4.4% | 7.1% | -2.1% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2024-06-20 | Other | Annual General Meeting |
| 2023-07-03 | Other | Annual General Meeting |
| 2022-12-22 | Bonus | Bonus 2:1 |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | ZIMLAB |
| BSE code | 541400 |
| ISIN | INE518E01015 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.